Clinical efficacy of intravitreal anti-vascular endothelial growth factor agents plus panretinal photocoagulation for the treatment of young and middle-aged patients with proliferative diabetic retinopathy
10.13389/j.cnki.rao.2025.0038
- VernacularTitle:玻璃体内注射抗VEGF药物联合全视网膜激光光凝术(PRP)治疗不同程度中青年PDR患者的临床疗效
- Author:
Rui SHI
1
;
Jing QIN
;
Xiaoyu GONG
;
Zhuoming LI
;
Dandan LIU
Author Information
1. 710068 陕西省西安市,陕西省人民医院眼科
- Publication Type:Journal Article
- Keywords:
proliferative diabetic retinopathy;
panretinal photocoagulation;
anti-vascular endothelial growth factor agents;
best-corrected visual acuity;
central macular thickness
- From:
Recent Advances in Ophthalmology
2025;45(3):216-220
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the clinical efficacy of intravitreal anti-vascular endothelial growth factor(VEGF)agents plus panretinal photocoagulation(PRP)for treating young and middle-aged patients with proliferative diabetic reti-nopathy(PDR).Methods A retrospective case study was conducted on young and middle-aged PDR patients presenting to the Ophthalmology Department of Shaanxi Provincial People's Hospital between January 1,2021 and October 1,2024.The patients were divided into three groups according to Chinese Clinical Guidelines for Diabetic Retinopathy(2022):se-vere non-proliferative diabetic retinopathy(NPDR),early proliferative diabetic retinopathy(E-PDR)and fibrous prolifera-tive diabetic retinopathy(F-PDR).A total of 53 patients(94 eyes)were included in this study,and the mean age was(41.66±10.24)year old.There were 17 cases(31 eyes)in the NPDR group,18 cases(33 eyes)in the E-PDR group,and 18 cases(30 eyes)in the F-PDR group.All the patients were treated with the intravitreal injection of anti-VEGF agents(0.5 mg ranibizumab)about 3.5 mm from the sclerocorneal limbus at the inferior temporal sector,once a month,for three consecutive months.Routine PRP treatment was given 1 week after the first injection.Best-corrected visual acuity[BCVA(logMAR)],intraocular pressure,slit-lamp,slit-lamp fundus,optos fundus photography and OCT examinations were per-formed.The central macular thickness(CMT),average macular thickness(AMT),and the incidence of diabetic vitreous hemorrhage and emerging epiretinal membrane were recorded 1 month and 3 months after the first injection.Results Pa-tients in the F-PDR group were younger than those in NPDR and E-PDR groups(all P＜0.05).The BCVA values of eyes in all the three groups increased to varying degrees after 3 months of treatment,compared with those before treatment(all P＜0.05).The eyes in the F-PDR group had poorer vision than those in NPDR and E-PDR groups after 3 months of treat-ment(all P＜0.05).CMT and AMT decreased in all groups after 3 months of treatment,compared with those before treat-ment(all P＜0.05).No significant difference was found in CMT and AMT among the three groups at the same period(all P＞0.05).Eyes in the F-PDR group had higher risk of diabetic vitreous hemorrhage and emerging epiretinal membrane than those in NPDR and E-PDR groups 3 months after treatment(all P＜0.05).Conclusion Intravitreal anti-VEGF therapy combined with PRP can effectively slow the progression of PDR and improve vision acuity in young and middle-aged pa-tients.PDR patients with fibrovascular proliferation are at higher risk of diabetic vitreous hemorrhage and emerging epireti-nal membrane during the treatment with intravitreal anti-VEGF therapy plus PRP.These patients need a close follow-up,and vitrectomy should be performed in a timely manner to relieve vitreous traction when necessary.
